Oral Plasma Kallikrein Inhibitor BCX7353 is Safe and Effective as an On-Demand Treatment of Angioedema Attacks in Hereditary Angioedema (HAE) Patients: Results of the ZENITH-1 Trial

Hilary Longhurst; Dumitru Moldovan; Anette Bygum; Marco Cicardi; Aarnoud Huissoon; Emel Aygoren-Pursun; Vesna Grivcheva-Panovska; David Hagin; Urs Steiner; Marcin Stobiecki; Werner Aberer; Claire Bethune; Saul N. Faust; Sorena Kiani; David Launay; Marcus Maurer; William Rae; Avner Reshef; Melanie T. Cornpropst; Sylvia M. Dobo; Sharon VanDyke; Sharon Murray; Phillip J. Collis; William P. Sheridan; Henriette Farkas

doi:10.1016/j.jaci.2018.12.112

Oral Plasma Kallikrein Inhibitor BCX7353 is Safe and Effective as an On-Demand Treatment of Angioedema Attacks in Hereditary Angioedema (HAE) Patients: Results of the ZENITH-1 Trial

Hilary Longhurst, Dumitru Moldovan, Anette Bygum, Marco Cicardi, Aarnoud Huissoon, Emel Aygoren-Pursun, Vesna Grivcheva-Panovska, David Hagin, Urs Steiner, Marcin Stobiecki, Werner Aberer, Claire Bethune, Saul N. Faust, Sorena Kiani, David Launay, Marcus Maurer, William Rae, Avner Reshef, Melanie T. Cornpropst, Sylvia M. DoboSharon VanDyke, Sharon Murray, Phillip J. Collis, William P. Sheridan, Henriette Farkas

KI, Dermato-Venerologi

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning

Originalsprog	Engelsk
Tidsskrift	Journal of Allergy and Clinical Immunology
Vol/bind	143
Udgave nummer	Suppl. 2
Sider (fra-til)	AB37
Antal sider	1
ISSN	0091-6749
DOI	https://doi.org/10.1016/j.jaci.2018.12.112
Status	Udgivet - 1. feb. 2019
Begivenhed	AAAAI Annual Meeting 2019 - San Francisco, USA Varighed: 22. feb. 2019 → 25. feb. 2019

Konference

Konference	AAAAI Annual Meeting 2019
Land	USA
By	San Francisco
Periode	22/02/2019 → 25/02/2019

Bibliografisk note

Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI), San Francisco, CA, FEB 22-25, 2019

Dokumenter og links

10.1016/j.jaci.2018.12.112

Citationsformater

Longhurst, H., Moldovan, D., Bygum, A., Cicardi, M., Huissoon, A., Aygoren-Pursun, E., Grivcheva-Panovska, V., Hagin, D., Steiner, U., Stobiecki, M., Aberer, W., Bethune, C., Faust, S. N., Kiani, S., Launay, D., Maurer, M., Rae, W., Reshef, A., Cornpropst, M. T., ... Farkas, H. (2019). Oral Plasma Kallikrein Inhibitor BCX7353 is Safe and Effective as an On-Demand Treatment of Angioedema Attacks in Hereditary Angioedema (HAE) Patients: Results of the ZENITH-1 Trial. Journal of Allergy and Clinical Immunology, 143(Suppl. 2), AB37. https://doi.org/10.1016/j.jaci.2018.12.112

Longhurst, Hilary ; Moldovan, Dumitru ; Bygum, Anette ; Cicardi, Marco ; Huissoon, Aarnoud ; Aygoren-Pursun, Emel ; Grivcheva-Panovska, Vesna ; Hagin, David ; Steiner, Urs ; Stobiecki, Marcin ; Aberer, Werner ; Bethune, Claire ; Faust, Saul N. ; Kiani, Sorena ; Launay, David ; Maurer, Marcus ; Rae, William ; Reshef, Avner ; Cornpropst, Melanie T. ; Dobo, Sylvia M. ; VanDyke, Sharon ; Murray, Sharon ; Collis, Phillip J. ; Sheridan, William P. ; Farkas, Henriette. / Oral Plasma Kallikrein Inhibitor BCX7353 is Safe and Effective as an On-Demand Treatment of Angioedema Attacks in Hereditary Angioedema (HAE) Patients: Results of the ZENITH-1 Trial. I: Journal of Allergy and Clinical Immunology. 2019 ; Bind 143, Nr. Suppl. 2. s. AB37.

@article{20b337db1cb24079ac7a6ac16636a51c,

title = "Oral Plasma Kallikrein Inhibitor BCX7353 is Safe and Effective as an On-Demand Treatment of Angioedema Attacks in Hereditary Angioedema (HAE) Patients: Results of the ZENITH-1 Trial",

author = "Hilary Longhurst and Dumitru Moldovan and Anette Bygum and Marco Cicardi and Aarnoud Huissoon and Emel Aygoren-Pursun and Vesna Grivcheva-Panovska and David Hagin and Urs Steiner and Marcin Stobiecki and Werner Aberer and Claire Bethune and Faust, {Saul N.} and Sorena Kiani and David Launay and Marcus Maurer and William Rae and Avner Reshef and Cornpropst, {Melanie T.} and Dobo, {Sylvia M.} and Sharon VanDyke and Sharon Murray and Collis, {Phillip J.} and Sheridan, {William P.} and Henriette Farkas",

note = "Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI), San Francisco, CA, FEB 22-25, 2019; AAAAI Annual Meeting 2019 ; Conference date: 22-02-2019 Through 25-02-2019",

year = "2019",

month = feb

day = "1",

doi = "10.1016/j.jaci.2018.12.112",

language = "English",

volume = "143",

pages = "AB37",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Mosby, Inc.",

number = "Suppl. 2",

}

Longhurst, H, Moldovan, D, Bygum, A, Cicardi, M, Huissoon, A, Aygoren-Pursun, E, Grivcheva-Panovska, V, Hagin, D, Steiner, U, Stobiecki, M, Aberer, W, Bethune, C, Faust, SN, Kiani, S, Launay, D, Maurer, M, Rae, W, Reshef, A, Cornpropst, MT, Dobo, SM, VanDyke, S, Murray, S, Collis, PJ, Sheridan, WP & Farkas, H 2019, 'Oral Plasma Kallikrein Inhibitor BCX7353 is Safe and Effective as an On-Demand Treatment of Angioedema Attacks in Hereditary Angioedema (HAE) Patients: Results of the ZENITH-1 Trial', Journal of Allergy and Clinical Immunology, bind 143, nr. Suppl. 2, s. AB37. https://doi.org/10.1016/j.jaci.2018.12.112

Oral Plasma Kallikrein Inhibitor BCX7353 is Safe and Effective as an On-Demand Treatment of Angioedema Attacks in Hereditary Angioedema (HAE) Patients: Results of the ZENITH-1 Trial. / Longhurst, Hilary; Moldovan, Dumitru; Bygum, Anette; Cicardi, Marco; Huissoon, Aarnoud; Aygoren-Pursun, Emel; Grivcheva-Panovska, Vesna; Hagin, David; Steiner, Urs; Stobiecki, Marcin; Aberer, Werner; Bethune, Claire; Faust, Saul N.; Kiani, Sorena; Launay, David; Maurer, Marcus; Rae, William; Reshef, Avner; Cornpropst, Melanie T.; Dobo, Sylvia M.; VanDyke, Sharon; Murray, Sharon; Collis, Phillip J.; Sheridan, William P.; Farkas, Henriette.

I: Journal of Allergy and Clinical Immunology, Bind 143, Nr. Suppl. 2, 01.02.2019, s. AB37.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning

TY - ABST

T1 - Oral Plasma Kallikrein Inhibitor BCX7353 is Safe and Effective as an On-Demand Treatment of Angioedema Attacks in Hereditary Angioedema (HAE) Patients: Results of the ZENITH-1 Trial

AU - Longhurst, Hilary

AU - Moldovan, Dumitru

AU - Bygum, Anette

AU - Cicardi, Marco

AU - Huissoon, Aarnoud

AU - Aygoren-Pursun, Emel

AU - Grivcheva-Panovska, Vesna

AU - Hagin, David

AU - Steiner, Urs

AU - Stobiecki, Marcin

AU - Aberer, Werner

AU - Bethune, Claire

AU - Faust, Saul N.

AU - Kiani, Sorena

AU - Launay, David

AU - Maurer, Marcus

AU - Rae, William

AU - Reshef, Avner

AU - Cornpropst, Melanie T.

AU - Dobo, Sylvia M.

AU - VanDyke, Sharon

AU - Murray, Sharon

AU - Collis, Phillip J.

AU - Sheridan, William P.

AU - Farkas, Henriette

N1 - Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI), San Francisco, CA, FEB 22-25, 2019

PY - 2019/2/1

Y1 - 2019/2/1

U2 - 10.1016/j.jaci.2018.12.112

DO - 10.1016/j.jaci.2018.12.112

M3 - Conference abstract in journal

VL - 143

SP - AB37

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - Suppl. 2

T2 - AAAAI Annual Meeting 2019

Y2 - 22 February 2019 through 25 February 2019

ER -

Longhurst H, Moldovan D, Bygum A, Cicardi M, Huissoon A, Aygoren-Pursun E et al. Oral Plasma Kallikrein Inhibitor BCX7353 is Safe and Effective as an On-Demand Treatment of Angioedema Attacks in Hereditary Angioedema (HAE) Patients: Results of the ZENITH-1 Trial. Journal of Allergy and Clinical Immunology. 2019 feb 1;143(Suppl. 2):AB37. https://doi.org/10.1016/j.jaci.2018.12.112